Corcept Therapeutics Incorporated (0I3Q.L)
USD 55.58
(-0.47%)
USD 55.58
(-0.47%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 114.81 Million USD | 40.72% |
| 2022 | 81.58 Million USD | 70.15% |
| 2021 | 47.95 Million USD | -0.92% |
| 2020 | 48.39 Million USD | 17.66% |
| 2019 | 41.13 Million USD | 14.85% |
| 2018 | 35.81 Million USD | 21.11% |
| 2017 | 29.56 Million USD | 8.02% |
| 2016 | 27.37 Million USD | -18.14% |
| 2015 | 33.43 Million USD | -12.04% |
| 2014 | 38.01 Million USD | -9.61% |
| 2013 | 42.06 Million USD | 12.49% |
| 2012 | 37.38 Million USD | 643.91% |
| 2011 | 5.02 Million USD | 30.21% |
| 2010 | 3.86 Million USD | 59.57% |
| 2009 | 2.41 Million USD | -15.66% |
| 2008 | 2.86 Million USD | -4.72% |
| 2007 | 3.01 Million USD | -15.02% |
| 2006 | 3.54 Million USD | -0.59% |
| 2005 | 3.56 Million USD | 95.34% |
| 2004 | 1.82 Million USD | 18.62% |
| 2003 | 1.53 Million USD | -96.48% |
| 2002 | 43.73 Million USD | 2221.39% |
| 2001 | 1.88 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 108.07 Million USD | -5.87% |
| 2024 Q3 | 145.42 Million USD | 22.91% |
| 2024 Q2 | 118.31 Million USD | 9.48% |
| 2023 FY | 114.81 Million USD | 40.72% |
| 2023 Q3 | 132.34 Million USD | 28.47% |
| 2023 Q4 | 114.81 Million USD | -13.25% |
| 2023 Q1 | 88.26 Million USD | 8.18% |
| 2023 Q2 | 103.01 Million USD | 16.71% |
| 2022 Q4 | 81.58 Million USD | 36.23% |
| 2022 Q1 | 60.31 Million USD | 25.78% |
| 2022 FY | 81.58 Million USD | 70.15% |
| 2022 Q2 | 54.03 Million USD | -10.4% |
| 2022 Q3 | 59.89 Million USD | 10.83% |
| 2021 FY | 47.95 Million USD | -0.92% |
| 2021 Q2 | 45.8 Million USD | 10.12% |
| 2021 Q1 | 41.59 Million USD | -14.05% |
| 2021 Q4 | 47.95 Million USD | 6.15% |
| 2021 Q3 | 45.17 Million USD | -1.39% |
| 2020 Q3 | 44.44 Million USD | 0.73% |
| 2020 Q1 | 36 Million USD | -12.46% |
| 2020 Q2 | 44.12 Million USD | 22.55% |
| 2020 Q4 | 48.39 Million USD | 8.88% |
| 2020 FY | 48.39 Million USD | 17.66% |
| 2019 FY | 41.13 Million USD | 14.85% |
| 2019 Q2 | 30.62 Million USD | -11.12% |
| 2019 Q1 | 34.45 Million USD | -3.78% |
| 2019 Q3 | 32.64 Million USD | 6.6% |
| 2019 Q4 | 41.13 Million USD | 25.99% |
| 2018 Q1 | 27.74 Million USD | -6.16% |
| 2018 Q4 | 35.81 Million USD | -10.93% |
| 2018 Q3 | 40.2 Million USD | 30.23% |
| 2018 Q2 | 30.87 Million USD | 11.26% |
| 2018 FY | 35.81 Million USD | 21.11% |
| 2017 Q2 | 20.39 Million USD | -20.84% |
| 2017 FY | 29.56 Million USD | 8.02% |
| 2017 Q4 | 29.56 Million USD | 21.33% |
| 2017 Q3 | 24.37 Million USD | 19.51% |
| 2017 Q1 | 25.75 Million USD | -5.9% |
| 2016 Q3 | 31.68 Million USD | 1.62% |
| 2016 Q4 | 27.37 Million USD | -13.6% |
| 2016 Q1 | 32.74 Million USD | -2.08% |
| 2016 FY | 27.37 Million USD | -18.14% |
| 2016 Q2 | 31.17 Million USD | -4.78% |
| 2015 FY | 33.43 Million USD | -12.04% |
| 2015 Q3 | 34.9 Million USD | -5.24% |
| 2015 Q1 | 37.65 Million USD | -0.96% |
| 2015 Q4 | 33.43 Million USD | -4.19% |
| 2015 Q2 | 36.82 Million USD | -2.19% |
| 2014 Q2 | 40.93 Million USD | -5.8% |
| 2014 Q1 | 43.46 Million USD | 3.33% |
| 2014 FY | 38.01 Million USD | -9.61% |
| 2014 Q4 | 38.01 Million USD | -1.19% |
| 2014 Q3 | 38.47 Million USD | -6.01% |
| 2013 Q1 | 37.13 Million USD | -0.67% |
| 2013 FY | 42.06 Million USD | 12.49% |
| 2013 Q2 | 39.31 Million USD | 5.86% |
| 2013 Q3 | 40.28 Million USD | 2.46% |
| 2013 Q4 | 42.06 Million USD | 4.41% |
| 2012 FY | 37.38 Million USD | 643.91% |
| 2012 Q4 | 37.38 Million USD | 10.38% |
| 2012 Q3 | 33.87 Million USD | 482.41% |
| 2012 Q1 | 3.57 Million USD | -28.97% |
| 2012 Q2 | 5.81 Million USD | 62.91% |
| 2011 Q3 | 2.71 Million USD | -29.64% |
| 2011 FY | 5.02 Million USD | 30.21% |
| 2011 Q2 | 3.85 Million USD | 20.65% |
| 2011 Q1 | 3.19 Million USD | -17.2% |
| 2011 Q4 | 5.02 Million USD | 85.26% |
| 2010 Q3 | 3 Million USD | 4.93% |
| 2010 Q4 | 3.86 Million USD | 28.67% |
| 2010 Q2 | 2.85 Million USD | 33.41% |
| 2010 FY | 3.86 Million USD | 59.57% |
| 2010 Q1 | 2.14 Million USD | -11.41% |
| 2009 Q4 | 2.41 Million USD | 2.59% |
| 2009 Q1 | 3.28 Million USD | 14.61% |
| 2009 Q2 | 2.13 Million USD | -34.93% |
| 2009 Q3 | 2.35 Million USD | 10.24% |
| 2009 FY | 2.41 Million USD | -15.66% |
| 2008 Q2 | 1.92 Million USD | -16.96% |
| 2008 Q4 | 2.86 Million USD | -12.96% |
| 2008 Q3 | 3.29 Million USD | 70.81% |
| 2008 Q1 | 2.32 Million USD | -22.82% |
| 2008 FY | 2.86 Million USD | -4.72% |
| 2007 Q4 | 3.01 Million USD | 12.23% |
| 2007 FY | 3.01 Million USD | -15.02% |
| 2007 Q2 | 1.44 Million USD | -35.07% |
| 2007 Q3 | 2.68 Million USD | 85.99% |
| 2007 Q1 | 2.22 Million USD | -37.3% |
| 2006 Q2 | 5.2 Million USD | -0.57% |
| 2006 FY | 3.54 Million USD | -0.59% |
| 2006 Q3 | 5.66 Million USD | 8.92% |
| 2006 Q4 | 3.54 Million USD | -37.51% |
| 2006 Q1 | 5.23 Million USD | 46.9% |
| 2005 Q2 | 1.51 Million USD | 19.98% |
| 2005 Q3 | 2.7 Million USD | 78.52% |
| 2005 Q4 | 3.56 Million USD | 31.91% |
| 2005 Q1 | 1.26 Million USD | -30.87% |
| 2005 FY | 3.56 Million USD | 95.34% |
| 2004 Q1 | 43.77 Million USD | 2746.79% |
| 2004 Q3 | 1.63 Million USD | 16.67% |
| 2004 Q2 | 1.4 Million USD | -96.8% |
| 2004 FY | 1.82 Million USD | 18.62% |
| 2004 Q4 | 1.82 Million USD | 11.63% |
| 2003 FY | 1.53 Million USD | -96.48% |
| 2003 Q4 | 1.53 Million USD | 0.0% |
| 2002 FY | 43.73 Million USD | 2221.39% |
| 2001 FY | 1.88 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Editas Medicine, Inc. | 150.05 Million USD | 23.487% |
| Dynavax Technologies Corporation | 375.02 Million USD | 69.385% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 76.447% |
| Perrigo Company plc | 6.04 Billion USD | 98.1% |
| Illumina, Inc. | 4.36 Billion USD | 97.37% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.779% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 41.344% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.833% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 99.442% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 55.235% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 98.385% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -207.873% |
| Waters Corporation | 3.47 Billion USD | 96.697% |
| Biogen Inc. | 12.04 Billion USD | 99.047% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -39.279% |
| Evolus, Inc. | 209.68 Million USD | 45.246% |
| Adicet Bio, Inc. | 37.12 Million USD | -209.3% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -66.977% |
| bluebird bio, Inc. | 424.62 Million USD | 72.961% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 82.625% |
| FibroGen, Inc. | 585.72 Million USD | 80.398% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 97.665% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -226.383% |
| Homology Medicines, Inc. | 118.53 Million USD | 3.139% |
| Geron Corporation | 146.12 Million USD | 21.43% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 97.166% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 81.413% |
| Myriad Genetics, Inc. | 312.9 Million USD | 63.307% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -472.029% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 54.223% |
| Zoetis Inc. | 9.29 Billion USD | 98.765% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -133.472% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 96.725% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 93.925% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 97.771% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -136.995% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 95.59% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 56.631% |
| Verastem, Inc. | 71.18 Million USD | -61.287% |
| Nektar Therapeutics | 267.04 Million USD | 57.007% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 71.099% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -185.417% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 95.227% |
| OPKO Health, Inc. | 622.47 Million USD | 81.556% |
| Exelixis, Inc. | 678.44 Million USD | 83.077% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 88.737% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -816.004% |
| uniQure N.V. | 624.01 Million USD | 81.601% |
| Imunon, Inc. | 8.53 Million USD | -1245.912% |
| Blueprint Medicines Corporation | 918.64 Million USD | 87.502% |
| Insmed Incorporated | 1.66 Billion USD | 93.091% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 93.039% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | 8.951% |
| TG Therapeutics, Inc. | 169.08 Million USD | 32.098% |
| Incyte Corporation | 1.59 Billion USD | 92.789% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 90.316% |